Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-312

7 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
A line graph illustrating the probability of achieving systolic blood pressure (SBP) below 140 mmHg at week 8. The x-axis represents baseline SBP in mmHg (ranging from 140 to 180), and the y-axis shows the percentage achieving SBP <140 mmHg (0 to 100%). Four lines represent different treatments: Valsartan and Hydrochlorothiazide 320 mg/25 mg (highest probability), Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo (lowest probability).*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)
A line graph showing the probability of achieving diastolic blood pressure (DBP) less than 90 mmHg plotted against baseline DBP in mmHg. The graph compares the effectiveness of Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with different markers representing each treatment group.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)
A line graph showing the probability of achieving systolic blood pressure (SBP) less than 130 mmHg at Week 8. The x-axis represents baseline SBP in mmHg from 140 to 180, and the y-axis shows the percentage achieving SBP <130 mmHg from 0 to 100%. The graph compares Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with Valsartan and Hydrochlorothiazide showing the highest probabilities across baseline SBP values.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)
A line graph displaying the probability of achieving diastolic blood pressure below 80 mmHg at week 8. It compares four groups: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The x-axis shows baseline diastolic blood pressure (mmHg), and the y-axis shows the percentage achieving target DBP.*
FDA Label Image

Valsartan 160mg/12.5mg (Valhyctz Fig5)

Valsartan 160mg/12.5mg (Valhyctz Fig5)
Label for Valsartan HCTZ 160 mg / 12.5 mg film-coated tablets, 30 count, proprietary name Valsartan and Hydrochlorothiazide. Manufactured by Aurobindo Pharma Limited, India, and packaged by Proficient Rx LP, Thousand Oaks, CA. The label includes dosage strength, quantity, product ID PV031230, storage instructions, and imprint description of the tablet.*
FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Valsartan Chemical Structure (Valhyctz Str1)
Chemical structure of Valsartan and Hydrochlorothiazide active ingredient, illustrating the molecular arrangement of atoms and bonds in the compound.*
FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)
Chemical structure of the active ingredient Valsartan and Hydrochlorothiazide, showing a bicyclic ring with attached sulfonamide, chlorine, and other functional groups consistent with its molecular composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.